Showing 4821-4830 of 5771 results for "".
- Two Chicago Ophthalmology Practices Receive Strategic Investment From MoonSail Capital And Plenary Partnershttps://modernod.com/news/two-chicago-ophthalmology-practices-receive-strategic-investment-from-moonsail-capital-and-plenary-partners/2477329/Chicago Eye Institute and Arbor Centers for EyeCare, two ophthalmology practices serving the Chicago market, announced that they have entered into a strategic partnership with private investment firms MoonSail Capital and Plenary Partners to form Ocular Partners.<
- Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for AMDhttps://modernod.com/news/gemini-therapeutics-and-singapore-eye-research-institute-enter-into-research-collaboration-to-explore-new-targets-for-amd/2477327/Gemini Therapeutics announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and potential biomarkers in patients d
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- Johnson & Johnson Vision Calls on Individuals Worldwide to Prioritize Your Eyes in 2020https://modernod.com/news/johnson-johnson-vision-calls-on-individuals-worldwide-to-prioritize-your-eyes-in-2020/2477309/Johnson & Johnson Vision announced the launch of “Prioritize Your Eyes,” a worldwide effort to raise awareness about the connection of eye health to overall health. Prioritize Your Eyes encourages everyone to take the single most important step to protect their eyes—getting an eye
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance
- Santen: VISIONARY Study Demonstrates Effectiveness of Tafluprost/Timolol Combination Therapy in Open-Angle Glaucomahttps://modernod.com/news/santen-visionary-study-demonstrates-effectiveness-and-tolerability-of-tafluprost-timolol-combination-therapy-in-open-angle-glaucoma/2477305/Santen has announced that the results of its real world evidence study, VISIONARY, have been published in Advances in Therapy. The study, which was conducted in 12 countries from across Europe with up to 6-mo
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- Alcon Receives FDA Approval for OTC Pataday Once Daily Relief for Allergy Reliefhttps://modernod.com/news/alcon-receives-fda-approval-for-otc-pataday-once-daily-relief-for-allergy-relief/2477298/Alcon announced that Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) have been approved by the FDA for sale over-the-counter (OTC) in the United States. The Pataday brand features th
- Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growthhttps://modernod.com/news/gyroscope-therapeutics-strengthens-senior-leadership-ahead-of-next-stage-of-company-growth/2477297/Gyroscope Therapeutics announced the strengthening of its leadership team with the hiring of Nadia Waheed, MD, MPH, from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO), and the promotion of Jane Hughes, PhD, formerly VP Translational Research, to Chief Scientific Off
- Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Diseasehttps://modernod.com/news/acucela-provides-update-on-emixustat-phase-3-clinical-trial-in-patients-with-stargardt-disease/2477295/Acucela announced that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride in patients with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, and placebo-contro